Cytokinetics, Inc. | Mid-cap | Healthcare
$33.36
-3.75%
| Cytokinetics Stock Comparison:
Cytokinetics vs VertexCytokinetics vs RegeneronCytokinetics vs Blueprint MedicinesCytokinetics vs Roivant SciencesCytokinetics vs Bio-TechneCytokinetics vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 18.5M
Gross Profit -320.9M -1,737.22%
Operating Income -536.2M -2,902.72%
Net Income -589.5M -3,191.11%
EPS (Diluted) -$5.26

Balance Sheet Metrics

Total Assets 1.4B
Total Liabilities 1.5B
Shareholders Equity -135.4M

Cash Flow Metrics

Operating Cash Flow -406.4M
Free Cash Flow -399.8M

Revenue & Profitability Trend

Cytokinetics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue18.5M7.5M94.6M70.4M55.8M
Cost of Goods Sold339.4M330.1M240.8M159.9M97.0M
Gross Profit-320.9M-322.6M-146.2M-89.5M-41.1M
Operating Expenses215.3M173.6M178.0M256.7M149.8M
Operating Income-536.2M-496.2M-324.2M-186.3M-93.9M
Pre-tax Income-589.5M-526.2M-389.0M-215.3M-127.3M
Income Tax-----
Net Income-589.5M-526.2M-389.0M-215.3M-127.3M
EPS (Diluted)-$5.26-$5.45-$4.33-$2.80-$1.97

Income Statement Trend

Cytokinetics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets1.1B628.1M795.2M535.7M474.2M
Non-Current Assets293.7M196.3M219.6M305.6M59.6M
Total Assets1.4B824.3M1.0B841.3M533.8M
Liabilities
Current Liabilities179.7M102.7M84.6M71.9M31.2M
Non-Current Liabilities1.4B1.1B1.0B525.6M389.2M
Total Liabilities1.5B1.2B1.1B597.5M420.4M
Equity
Total Shareholders Equity-135.4M-386.3M-107.9M243.9M113.4M

Balance Sheet Composition

Cytokinetics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income-589.5M-526.2M-389.0M-215.3M-127.3M
Operating Cash Flow-406.4M-433.1M-305.7M-153.0M8.8M
Investing Activities
Capital Expenditures-3.9M-1.4M-11.3M-48.9M-11.1M
Investing Cash Flow-553.1M239.3M-262.1M-147.8M-196.5M
Financing Activities
Dividends Paid-----
Financing Cash Flow877.6M202.9M498.6M307.6M225.0M
Free Cash Flow-399.8M-415.7M-310.9M-191.4M-2.1M

Cash Flow Trend

Cytokinetics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -6.21
Forward P/E -6.06
Price to Book -14.52
Price to Sales 202.84
PEG Ratio -6.06

Profitability Ratios

Profit Margin -1,737.22%
Operating Margin -9,856.30%
Return on Equity 435.49%
Return on Assets -34.12%

Financial Health

Current Ratio 5.99
Debt to Equity -3.42
Beta 0.59

Per Share Data

EPS (TTM) -$5.29
Book Value per Share -$2.24
Revenue per Share $0.17

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
cytk3.9B-6.21-14.52435.49%-1,737.22%-3.42
Vertex 114.1B32.826.92-5.64%-8.91%10.00
Regeneron 55.3B13.021.8415.96%31.94%9.20
Blueprint Medicines 8.3B-120.0024.19-47.71%-27.70%208.50
Roivant Sciences 7.8B1.951.71-12.54%96.86%1.93
Bio-Techne 7.9B60.873.926.53%10.89%20.99

Financial data is updated regularly. All figures are in the company's reporting currency.